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Abstract:  
Obesity drugs have had a chequered history. In the recent past, only the low efficacy, 
pancreatic lipase inhibitor orlistat was available worldwide and it was little used. The 5HT2C 
agonist lorcaserin, and two combinations of old drugs have been approved in the United 
States but not in Europe. The diabetes drug liraglutide has been approved in both the US 
and Europe and seems likely to be most widely accepted. In view of regulators’ caution in 
approving obesity drugs, some (like beloranib) may initially be progressed for niche obesity 
markets. New drug targets have been identified in brown adipose tissue with the aim of not 
only activating thermogenesis but also increasing the capacity for thermogenesis in this 
tissue. Attempts are being made to match the efficacy of bariatric surgery by mimicking 
multiple gut hormones. Unapproved pharmacotherapies are tempting for some patients. 
Others remain optimistic about more conventional routes to pharmacotherapy. 
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Introduction 
Obesity and the diseases with which it is associated are some of the most common health 
issues that we face today. There are a number of pharmacotherapies for the associated 
diseases, such as diabetes, cardiovascular diseases and some cancers, but pharmacotherapy 
is little used for obesity itself. I shall describe drugs and drug discovery approaches that 
offer new hope, whilst also highlighting some less conventional routes. Table 1 gives an 
approximate guide to the relative efficacy of drugs that are approved in some jurisdictions 
or under clinical investigation. 
The first drugs for obesity increased metabolic rate, but most of those that followed 
interacted with central neurotransmitters and reduced energy intake. One, orlistat, reduces 
fat absorption. Today there is a focus on reducing energy intake by mimicking or opposing 
gut hormones, together with a renewed interest in thermogenic drugs. Some experimental 
drugs act on peripheral metabolic pathways [1] but this will not be discussed here. 
Disappointments past and present 
From thyroid hormones in the 1890s and the uncoupling agent dinitrophenol in the 1930s, 
through amphetamines and related compounds in the second half of the 20th century, to 
sibutramine and rimonabant in the 21st, anti-obesity drugs have come and – when found to 
be unsafe – gone [2,3]. In many countries, until very recently, the only remaining drug was 
orlistat, which inhibits gastric and pancreatic lipases and thereby the digestion of fat. 
Orlistat was approved by the Food and Drug Administration (FDA) of the United States in 
1999 and marketed in most countries under the name Xenical. Despite massive market 
potential, it made little headway until 2007 when the FDA approved a half-strength version 
for sale without a prescription. This was sold under the name alli. In 2007 alli had the largest 
market share of all obesity drugs (sibutramine and rimonabant were still available) but its 
sales were nevertheless below $260M in that year. The following year sales dropped by 
50%. The approval of alli by the European Medicines Agency (EMA) in 2009 saw only a 
temporary recovery in sales.  
The median duration of use of orlistat (as Xenical) in the United States between 2002 and 
2011 was 48 days [4]. Only 10% and 2% of patients were still using it after one and two 
years respectively. Two other anti-obesity drugs, phentermine and sibutramine, fared little 
better, each with median durations of use of 60 days. (Phentermine should not be used for 
more than 84 days, but some patients take it for longer.) For comparison, the figure for 
captopril, which is used to treat hypertension, was 164 days. The short duration of use of 
orlistat is probably due to its gastrointestinal side-effects and limited efficacy. In meta-
analyses of clinical trials, average weight loss with the higher dose of orlistat (as in Xenical) 
reaches only about 2.7 to 2.9 kg more than placebo [5,6] (Table 1). The lower dose elicited 
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weight loss relative to placebo of 0.8 kg [6]. A recent analysis that focussed on maintenance 
of weight loss after ≥5% weight loss before introducing orlistat, found weight loss over ≥ 12 
months of 2.34 kg. The figure for the alli dose was 0.70 kg [7]. Weight loss in routine clinical 
practice may be less well maintained, or even insignificant after three years [8]. Another 
pancreatic lipase inhibitor, cetilistat (brand name Cametor or Oblean in Japan from Takeda) 
was approved in Japan in September 2013. It has not been launched in Japan, but is being 
sold by an Indian company [9]. It has similar efficacy to orlistat, but is claimed to show a 
reduced incidence of gastrointestinal side-effects [10,11]. 
In the United States, the amphetamine-related drugs benzphetamine, diethylpropion 
phendimetrazine and phentermine remain available for short-term use. Of these 
phentermine is prescribed most [4].  These drugs have not been available in Europe since 
2000. 
Two drugs were launched in the United State in 2012 and 2013: a combination of 
phentermine and the anti-convulsant topiramate (brand name Qsymia) by Vivus in 
September 2012, and the 5HT2C receptor agonist lorcaserin (brand name Belviq) by Arena 
and Eisai in June 2013 (though approved in 2012 by the FDA before Qsymia). These, like 
most other new drugs of the past 40 years are approved for long-term use, unlike the 
amphetamine-related drugs.   
So far, Qsymia and Belviq have not revolutionised the pharmacotherapy of obesity. First, 
phentermine/topiramate has been rejected by the EMA on the grounds that its benefits do 
not outweigh its risks, while the new drug application for lorcaserin was withdrawn when it 
became clear that it would suffer a similar fate [12,13]. The different stances of the FDA and 
EMA and the particular focus of regulatory authorities on cardiovascular risk are discussed 
by Pucci & Finer [14]. A number of articles and letters have been published recently that 
question the value of these drugs, or support them provided they are discontinued in 
patients who do not achieve weight loss of at least 5 kg within 12 weeks [6,13]. Lorcaserin 
elicits average weight loss of about 3.2 kg more than placebo (better than orlistat but still 
poor) and there are worries about its preclinical safety and psychiatric risks. There is no 
evidence that it increases valvulopathy [15], which was the main cause of the demise of the 
5HT releasers and reuptake inhibitors fenfluramine and dexfenfluramine. This may remain a 
concern in the minds of some regulators, however. The standard (ie middle) dose of 
phentermine/topiramate elicits greater weight loss (6.7 kg; Table1), but with one of its 
components, phentermine, unavailable in Europe owing to psychiatric and cardiovascular 
concerns, it is unsurprising that it was not approved [6,12]. CNS and gastrointestinal side-
effects of topiramate add to these worries. 
 Second, even in the US, sales of Qsymia (phentermine/topiramate) and Belviq (lorcaserin) 
have been very low. In the third quarter of 2014, sales of Qsymia were about $12.5M [16]. 
At a cost of $500 per person per quarter, this corresponds to 25,000 patients, whereas there 
are about 83 million people in the United State with a BMI > 30 kg.m-2 [17]. One reason for 
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these limited sales is that many patients find the side-effects of Qsymia (paraesthesia; 
cognitive changes; dry mouth; depression) unacceptable [18]. In the same period sales of 
Belviq totalled $20M  [19], which corresponds to about 37,000 patients. Thus less than one 
in a thousand of obese subjects in the United States were taking Qsymia or Belviq in the 
third quarter of 2014. Doubts as to whether the benefits outweigh the risks of these drugs 
are probably enhanced by previous failures of anti-obesity drugs. 
Looking to the horizon, prospects for orlistat, phentermine/topiramate and lorcaserin seem 
poor, though some analysts are optimistic. 
Recent approvals 
The combination of the dopamine and noradrenaline reuptake inhibitor bupropion and the 
μ-opioid antagonist naltrexone is branded by its makers Orexigen as Contrave in the United 
States and Mysimba in Europe. Already launched in the United States in October 2014, it 
was recommended for approval in Europe in December 2014, despite the FDA being 
concerned about its cardiovascular effects [14]. The European Commission is being lobbied 
by a consortium of European consumer groups that is concerned by its cardiovascular safety 
[20]. This concern was being addressed in the “Light Study” demanded by the FDA. This 
study was due to continue to 2017, but has now been abandoned. A provisional evaluation 
in 2014 was key to the approval by the FDA [21]. The FDA objected to Orexigen releasing 
provisional data [22,23], which now appears to have given a misleading impression of 
cardiovascular safety. A new study is planned. Weight loss after a year’s treatment is 4 to 5 
kg greater than for placebo [6,21]. Nausea is the most reported adverse event [24]. 
Liraglutide (Novo Nordisk), which is an analogue of glucagon-like peptide-1 (GLP-1), was 
approved by the FDA for the treatment of obesity in December 2014. A month later, it was 
recommended for approval by the EMA. These approvals always seemed likely because 
liraglutide has been widely used as a treatment for type 2 diabetes (under the brand name 
Victoza) since 2009 in Europe and 2010 in the United States. However, the dose level for use 
in obesity (under the brand name Saxenda) is 3 mg once daily, compared with a maximum 
dose of 1.8 mg for diabetes. Being a peptide, liraglutide is administered by subcutaneous 
injection [14,25]. This may restrict its widespread use in obesity and thereby mitigate the 
impact of any unforeseen risks.  Weight loss in a 20-week trial in non-obese patients was 4.4 
kg higher than in the placebo group [26]. A greater benefit (5.9 kg) was reported for a trial 
of weight maintenance following a 12-week low-calorie diet [27]. The mechanism of action 
of liraglutide endows it with anti-diabetic activity beyond what might be predicted from its 
anti-obesity activity. There is however some concern about a slight increase in heart rate. 
The clinical relevance of this is being addressed in a long term study [14]. A study in mice 
showed that injection of liraglutide in the ventromedial nucleus of the hypothalamus 
stimulates brown adipose tissue thermogenesis [28]. This response might be mediated by 
activation of the sympathetic nervous system, which might also be responsible for the 
increase in heart rate in humans. 
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The horizon for bupropion/naltrexone and liraglutide (as an anti-obesity drug) is unclear. 
Sales of bupropion/naltrexone have passed those of phentermine/topiramate in the United 
States, but cardiovascular safety is an unresolved issue.  The outlook for liraglutide seems 
hopeful in the short-term, but in the longer term it may be challenged by GLP-1 receptor 
agonists that can be administered once a week, rather than once a day [29].  The first long-
acting GLP-1 receptor agonist, a formulation of exenatide, does not, however, appear to be 
a contender. The once-weekly formulation of exenatide elicited weight loss from baseline of 
2.4 kg over 24 weeks in type 2 diabetic subjects, which was not significantly greater than the 
effect (1.4 kg) of the twice daily formulation [30]. At the dose used to treat type 2 diabetes 
(1.8 mg), liraglutide (once daily) elicits average weight loss of about 2.7 kg compared to 
placebo [31]. 
Niche obesity markets 
Regulators are understandably concerned about approving obesity drugs that could 
potentially be used by over half the adult population within their jurisdictions.  A more 
cautious approach is to focus on a minor segment of the obese population. This would seem 
to fit with the recent announcement by the EMA of an adaptive licensing initiative, 
especially If the unmet need is serious, or there are reasons for adopting a compassionate 
approach [32]. As experience is gained with new drugs, their use might be extended to a 
larger patient population.  
Beloranib and Prader-Willi syndrome 
Zafgen Inc. are developing their methionine aminopeptidase inhibitor beloranib for the 
treatment of obesity in patients with the rare genetic disorder Prader-Willi syndrome. 
Beloranib is an analogue of the anti-microbial agent fumagillin. It was originally identified as 
an angiogenesis inhibitor [33].  A phase 3 clinical trial of beloranib in Prader-Willi Syndrome 
was announced in October 2014. A phase 2 trial in hypothalamic injury-associated obesity, 
which affects only about 500 patients each year has been completed [34]. Although not the 
target market, ‘normal’ obese patients treated for 12 weeks with beloranib at its highest 
dose level lost 10.5 kg more body weight than patients treated with placebo [35]. This is 
significantly more than most anti-obesity drugs have achieved (Table 1).  
Metformin and anti-psychotic drug-induced weight gain 
Metformin is an old drug and the first-line drug for the treatment of type 2 diabetes. It has 
been known for many years that metformin causes only a modest reduction in body weight 
in diabetic patients [36], though it appears to be at least as effective as orlistat at reducing 
waist circumference [37]. Recently, there have been reports of its effect on body weight in 
non-diabetic patients, including children [38]. Children are unlikely to be a niche market for 
a novel obesity drug, but metformin has also been studied in patients with mood disorders 
[39] and schizophrenia [40]. These patients include schizophrenic patients newly treated 
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with anti-psychotic drugs, notably olanzapine, that promote weight gain [41,42]. The body 
weight benefits achieved in some of these studies have been markedly greater than in type 
2 diabetic patients. Thus a meta-analysis of fourteen studies in children showed a 1.38% 
decrease in BMI over 6 months compared to placebo [38], and a meta-analysis of twelve 
studies in olanzapine-treated patients showed a 5.02 kg difference in body weight gain 
between those treated with metformin and placebo [41].  
In addition to metformin, mifepristone, amantadine, zonisamide and betahistine reduce 
anti-psychotic drug-induced weight gain [43,44,45]. Any novel drug that targets this market 
would preferably have advantages over these drugs, as they are approved for other 
indications. 
Eating disorders 
Binge eating disorder involves episodes of uncontrollable excessive eating without 
subsequent purging. A large proportion (85%) of those diagnosed are obese or overweight 
[46]. In January 2015, the FDA approved the amphetamine-like drug lisdexamfetamine for 
the treatment of binge eating disorder [47]. Lisdexamfetamine was already used for the 
treatment of attention deficit hyperactivity disorder. Weight loss in an 8-week study was 4.2 
kg higher in subjects treated with lisdexamfetamine than in those treated with placebo [48]. 
Eleven- and twelve-week studies have recorded weight losses of between 5.2 and 6.25% 
[49]. The amphetamine-like nature and side-effects of lisdexamfetamine will raise concerns 
for the EMA. 
A number of other drugs have been investigated for the treatment of binge eating disorder 
but few of these have been used as anti-obesity drugs. Two exceptions are topiramate [50] 
and sibutramine [51].   Regulatory authorities might feel more comfortable approving drugs 
for binge eating disorder, if they are less effective or ineffective in general obesity and 
therefore less likely to be used off-label. Studies in rodents indicate that the aldehyde 
dehydrogenase-2 inhibitor GS455534 and the orexin-1 receptor antagonist GSK1059865 
selectively inhibit intake of palatable food [52,53]. Drugs that are unlikely to be approved for 
general obesity, however, would be less attractive to the pharmaceutical industry. 
The other major eating disorder is bulimia nervosa, for which fluoxetine if the only drug 
approved by the FDA [54]. Fluoxetine is an SSRI antidepressant that causes some short-term 
weight loss [55]. Bulimia might offer another route to entry into the wider obesity market.  
Post-bariatric surgery 
Bariatric surgery is the most effective treatments for obesity [56] but regain of between 20 
and 30% of the weight initially lost is common [57]. There is anecdotal evidence that 
topiramate reduces binge eating and weight regain following bariatric surgery [58]. 
Prevention of weight regain following bariatric surgery might offer a niche indication for the 
entry of a drug into the obesity market. 
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Phase 2 Clinical Trials and Novel targets 
Among drugs in phase 2 clinical trials for obesity are compounds targeting melanocortin-4 
receptor, the histamine H3 receptor, the intestinal microsomal transfer protein and the 
sodium-glucose cotransporter 2 (SGLT-2) [59]. SGLT-2 is the target of approved drugs for 
diabetes, which lower blood glucose (and body weight) by increasing renal glucose 
excretion. The SGLT-2 inhibitor canagliflozin caused weight loss over 12 weeks in non-
diabetic obese subjects, but at the most effective dose this was only 1.6% greater than with 
placebo [60]. Thus, although like liraglutide there will be ample experience of SGLT-2 
inhibitors from their use in diabetes, weight loss may prove insufficient for them to be used 
to treat obesity alone. 
This rest of this section will address two high-profile areas for research into novel targets for 
anti-obesity drugs. 
 Brown adipose tissue  
Brown adipose tissue contains uncoupling protein-1 (UCP-1). When UCP-1 is activated by 
fatty acids, brown adipose tissue burns fat without synthesising ATP.  Brown adipocytes, 
including human brown adipocytes [61], express the 3-adrenoceptor (3-adrenergic 
receptor). From the 1970s until about 2009 the prevailing view, despite some evidence to 
the contrary, was that brown adipose tissue is present in human neonates and infants but 
does not occur in significant amounts in adult humans. This partly explained why 3-
adrenoceptor agonists performed poorly in clinical trials for obesity and type 2 diabetes, 
despite performing well in rodent models.  Recent studies in which positron emission 
tomography combined with computed tomography is used to measure and localise the 
uptake of 18F-fluorodeoxyglucose glucose into tissues, together with surgical intervention to 
demonstrate that sites of high uptake have multilocular adipocytes that express UCP-1, 
have, however, demonstrated unequivocally that active brown adipose tissue is present in 
at least some adult humans [62]. 
These studies have led to a surge in interest in brown adipose tissue as a target for 
thermogenic anti-obesity drugs, spurred on by the recognition of a lineage of ‘beige’ or 
‘brite’ adipocytes that derive from white adipocytes in response to certain stimuli, such as 
cold [63]. Unfortunately, there tends to be less functional brown adipose tissue in obese 
than in lean subjects. Therefore, it is important not only to acutely activate thermogenesis 
in brown adipocytes but also to increase their number and their capacity for thermogenesis 
[64].  Among the approaches being investigated are mimetics of irisin and fibroblast growth 
factor-21 [65,66], though recent work casts doubt on the role of irisin because many studies 
have used commercial ELISA kits to detect irisin that cross-react with other proteins [67].  
If brown adipose tissue plays a significant role in adult humans, should 3-adrenoceptor 
agonists be reconsidered for the treatment of obesity and type 2 diabetes? In rodents 
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[68,69], dogs [70] and rhesus monkeys [71] 3-adrenoceptor agonists not only activate 
thermogenesis but, when given repeatedly, they increase the capacity of brown fat to 
respond to acute activation. Moreover, in phaeochromocytoma, an adrenal medulla 
neuroendocrine tumour, over-secretion of noradrenaline and adrenaline causes a marked 
increase in brown adipose tissue mass in humans, associated with reduced body fat content 
[72,73]. 
The only 3-adrenoceptor agonist approved for use in humans is mirabegron, which is used 
in the treatment of overactive bladder.  From 210 to 250 min after giving four times its 
therapeutic dose, it increased resting metabolic rate by 13% [74]. If this increase could be 
sustained over 24 hours, one would expect weight loss of 5 kg in the first year [75]. 
However, the subjects were twelve lean young men selected from fifteen candidates, the 
other three not showing detectable brown adipose tissue activation in response to cold. 
There is less active brown fat not only in obese than lean subjects, but also in old than in 
young subjects, emphasising the need to increase thermogenic capacity during chronic 
treatment with 3-adrenoceptor agonists. 
Mimicry of bariatric surgery  
Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy, the most effective bariatric 
surgery procedures, elicit mean weight loss of about 40 kg [76]. Weight loss cannot easily be 
explained in terms of malabsorption, raising the possibility that changes in gut hormones, 
signalling molecules released by gut microbiota, or neuronal signalling from the gut play a 
role [77]. Of these, gut hormones offer the most obvious targets for pharmacotherapy [78]. 
The GLP-1 receptor agonist liraglutide elicits far less weight loss than bariatric surgery (Table 
1), and it has been hypothesised that no single gut hormone is dominant in mediating the 
effects of bariatric surgery. Therefore, compounds have been investigated in rodents that 
mimic two [78] or even three gut hormone receptors, such as a ‘triagonist’ of the GLP-1, 
glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors [79]. 
Vertical sleeve gastrectomy causes weight loss and improves glucose tolerance in diet-
induced obese mice, but these effects are substantially reduced in mice in which the 
farnesoid-x receptor (FXR), a bile acid receptor, is disrupted [80]. This suggests that FXR 
agonists should cause weight loss in diet-induced obese mice. Inconsistent results have 
been obtained with such compounds, however [81,82,83]. Recently, the gut-restricted FXR 
agonist fexaramine has been reported to reduce obesity and insulin resistance in mice. 
These effects are associated with browning of adipose tissue [84], which raises the 
possibility that fexaramine increases sympathetic activity.  
 
10 
 
Less conventional routes 
Whilst regulators can ensure that only effective and safe drugs are available to patients 
through pharmacies, they can do little to prevent patients from taking substances that 
are classified as foods or easily obtained because they are approved for other uses. Some of 
these substances might be as effective as previously approved anti-obesity drugs, but 
without the backing of a pharmaceutical company it is difficult to evaluate them in large 
clinical trials. They might also, of course, be unsafe by the standards demanded of 
regulators for anti-obesity drugs. 
  
Cold, capsaicin and nicotine  
The recent interest in brown adipose tissue has led to a reappraisal of earlier work [85] on 
the benefit of reduced ambient temperature in the treatment of obesity [86]. Some fat loss 
was observed in a 6-week study [87]. However, skeletal muscle made a far greater 
contribution that brown adipose tissue to systemic glucose uptake in response to cold [88], 
raising the possibility that skeletal muscle might also make a greater contribution to cold-
stimulated thermogenesis.  
Reducing the ambient temperature is not a comfortable way to lose weight, and so 
capsinoids, which like cold activate the sympathetic nervous system, have been investigated 
as an alternative approach. They were ineffective in reducing body fat in a 6-week study 
[87], but reduced abdominal fat in a 12-week study [89].  
Nicotine also raises sympathetic activity as well as reducing appetite [90].  This has led to 
speculation that e-cigarettes might have an anti-obesity effect. It is unclear, however, 
whether smoking normal cigarettes has a long-lasting anti-obesity effect [91] or whether 
nicotine patches reduce weight gain following smoking cessation [92]. Moreover, smoking 
increases the incidence of the metabolic syndrome [91]. 
Any treatment that activates the sympathetic nervous system is likely to have adverse 
cardiovascular effects. The cardiovascular effects of sibutramine that led to its withdrawal 
as an anti-obesity drug were linked to increased sympathetic activity [3], and the adverse 
cardiovascular effects of smoking may be due in large part to increased sympathetic activity 
[93]. The incidence of myocardial infarction increases in cold weather, again potentially due 
to increased sympathetic activity [94]. 
 
Testosterone 
Weight loss in response to most anti-obesity drugs plateaus after about 6 months of 
treatment. By contrast, in recent studies restoration of testosterone levels to the 
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physiological range in obese hypogonadal men with and without type 2 diabetes caused 
weight loss that continued for five to six years, reaching 15 to 20% [95,96]. These were 
uncontrolled studies, but weight loss was so large that it is very unlikely that it can be 
attributed to a placebo effect.  Moreover, weight loss has also been demonstrated in 
controlled studies of shorter duration. Markers of metabolic and cardiovascular health are 
improved in hypogonadic men [96,97] but not in men without hypogonadism [98]. However, 
some studies have suggested that testosterone might increase cardiovascular risk, and 
although these have been strongly criticised, the FDA has decided to review the risks 
associated with testosterone treatment [97,99]. For this and possibly commercial reasons, 
testosterone may never be approved for the treatment of obesity in hypogonadic men. This 
is a controversial area that requires further randomised clinical trials [100]. 
Conclusions 
Very few patients are currently treated with anti-obesity drugs. Of recently approved drugs, 
liraglutide seems best placed to make an impact in both the United States and other 
markets. Some drugs may be targeted to niche obesity markets because they are more 
effective in these than in the general obese population, or because they present too large a 
risk to be released directly to a large number of patients. Pharmaceutical companies will 
continue to explore new drug targets as long as the large unmet medical need remains. 
Patients, meanwhile, will be tempted to explore unapproved and potentially risky 
pharmacotherapies. 
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Table 1 Average weight loss in response to pharmacotherapy: a approximate guide to 
relative efficacy. Studies are of 6 months or longer duration in obese subjects and weight 
loss is relative to the response to placebo and given in kg, unless indicated otherwise. 
Drug Other details Weight loss Reference/ 
reference 
source 
Orlistat Xenical dose 2.7 – 2.9 [5,6] 
 alli dose 0.8 [6] 
Lorcaserin  3.2 [6] 
Phentermine/topiramate 7.5/46 mg 6.7 [6,18] 
Bupropion/naltrexone 360/32 mg 4 – 5 [6,21] 
Liraglutide  3 mg 4.4/5.9 [26,27] 
Beloranib 12 week study 10.5 [35] 
Metformin Olanzapine-treated; 12 weeks 5.0 [41] 
 Children 1.38% BMI [38] 
Lisdexamfetamine 11-12 weeks 
Placebo ‘did not reduce weight’ 
3.1 – 4.9 
(5.2 – 6.25%) 
[49] 
Testosterone 5 to 6 years. No placebo. 17.5/21.5 [95,96] 
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